Morphosys AG ADR (NASDAQ: MOR) stock jumped 0.34% on Monday to $5.86 against a previous-day closing price of $5.84. With 0.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.3 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.98 whereas the lowest price it dropped to was $5.73. The 52-week range on MOR shows that it touched its highest point at $8.67 and its lowest point at $3.17 during that stretch. It currently has a 1-year price target of $10.69. Beta for the stock currently stands at 0.90.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MOR was down-trending over the past week, with a drop of -18.61%, but this was down by -11.08% over a month. Three-month performance dropped to -26.10% while six-month performance fell -5.48%. The stock gained 46.87% in the past year, while it has gained 63.69% so far this year. A look at the trailing 12-month EPS for MOR yields 0.57 with Next year EPS estimates of -1.64. For the next quarter, that number is -0.51. This implies an EPS growth rate of -66.05% for this year and 15.69% for next year.
Float and Shares Shorts:
At present, 136.66 million MOR shares are outstanding with a float of 136.28 million shares on hand for trading. On Oct 30, 2023, short shares totaled 61960.0, which was 0.05% higher than short shares on Sep 28, 2023. In addition to Dr. Jean-Paul Kress M.D. as the firm’s Chairman of Management Board, MD & CEO, Dr. Lucinda Crabtree Ph.D. serves as its CFO & Member of Management Board.
Institutional Ownership:
Through their ownership of 9.90% of MOR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.55% of MOR, in contrast to 4.33% held by mutual funds. As the largest shareholder in MOR with 4.91% of the stake, T. Rowe Price Investment Manageme holds 6,720,852 shares worth 6,720,852. A second-largest stockholder of MOR, Opaleye Management, Inc., holds 1,209,380 shares, controlling over 0.88% of the firm’s shares. Logos Global Management LP is the third largest shareholder in MOR, holding 950,000 shares or 0.69% stake. With a 1.62% stake in MOR, the T Rowe Price Small Cap Stock Fund is the largest stakeholder. A total of 2,221,879 shares are owned by the mutual fund manager. The T Rowe Price Small Cap Value Fund, which owns about 1.13% of MOR stock, is the second-largest Mutual Fund holder. It holds 1,551,500 shares valued at 12.37 million. T Rowe Price Institutional Small holds 0.80% of the stake in MOR, owning 1,100,713 shares worth 8.77 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MOR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With MOR analysts setting a high price target of $17.00 and a low target of $5.44, the average target price over the next 12 months is $10.69. Based on these targets, MOR could surge 190.1% to reach the target high and fall by -7.17% to reach the target low. Reaching the average price target will result in a growth of 82.42% from current levels.
